Results 41 to 50 of about 259,973 (292)

PD-L1 Expression in Lung Cancer [PDF]

Journal of Thoracic Oncology, 2016
Immunotherapies targeted against programmed death ligand 1 (PD-L1) and its receptor (PD-1) have improved survival in a subset of patients with advanced lung cancer. PD-L1 protein expression has emerged as a biomarker that predicts which patients are more likely to respond to immunotherapy. The understanding of PD-L1 as a biomarker is complicated by the
Hui, Yu, Theresa A, Boyle, Caicun, Zhou, David L, Rimm, Fred R, Hirsch   +4 more
openaire   +5 more sources

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?

Frontiers in Immunology, 2017
PD-1–PD-L1 interaction is known to drive T cell dysfunction, which can be blocked by anti-PD-1/PD-L1 antibodies. However, studies have also shown that the function of the PD-1–PD-L1 axis is affected by the complex immunologic regulation network, and some
Zijun Y. Xu-Monette, Mingzhi Zhang, Jianyong Li, Ken H. Young, Ken H. Young   +4 more
doaj   +1 more source

Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas

Diagnostic Pathology, 2020
Background The prognostic potential of PD-L1 is currently unclear in gastric carcinomas, although the immune checkpoint PD-1/PD-L1 inhibitors have produced promising results in clinical trials.
Euno Choi, Mee Soo Chang, Sun-ju Byeon, Heejin Jin, Kyeong Cheon Jung, Haeryoung Kim, Kook Lae Lee, Won Kim, Jin Hyun Park, Ki Hwan Kim, Jin-Soo Kim, In Sil Choi, Dong-Seok Han, Hye Seong Ahn, Seung Chul Heo   +14 more
doaj   +1 more source

PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition

Frontiers in Immunology, 2019
Cancer immunotherapy involves blocking the interactions between the PD-1/PD-L1 immune checkpoints with antibodies. This has shown unprecedented positive outcomes in clinics.
Yilun Wu, Weiyu Chen, Zhi Ping Xu, Wenyi Gu   +3 more
doaj   +1 more source

Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer. [PDF]

, 2017
Cancer-Testis antigens (CTA) are immunogenic molecules with normal tissue expression restricted to testes but with aberrant expression in up to 30% of non-small cell lung cancers (NSCLCs). Regulation of CTA expression is mediated in part through promoter
Barnett, Stephen A, Boutros, Paul C, Chüeh, Anderly C, Jayachandran, Aparna, John, Thomas, Liew, Mun-Sem, Mariadason, John M, Russell, Prudence A, Starmans, Maud HW, Walkiewicz, Marzena, Wright, Gavin   +10 more
core   +2 more sources

Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease

BMC Research Notes, 2020
Objective Programmed death-1 (PD-1) and its ligand PD-L1 are now used as predictive biomarkers to guide clinical decisions. Precise characterization of PD-L1-positive cells may contribute to our knowledge of which patients derive benefit from the PD-L1 ...
Markus Tiemann, Vera Samoilova, Dmitri Atiakshin, Igor Buchwalow   +3 more
doaj   +1 more source

Comparative evaluation of PD‐L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non‐small cell lung cancer patients

Molecular Oncology, 2023
Alternative sources of tumour information need to be explored in patients with non‐small cell lung cancer (NSCLC). Here, we compared programmed cell death ligand 1 (PD‐L1) expression on cytology imprints and circulating tumour cells (CTCs) with PD‐L1 ...
Mustafa Abdo, Yassine Belloum, David Heigener, Lutz Welker, Sönke vonWeihe, Milena Schmidt, Nadine Heuer‐Olewinski, Iris Watermann, Marlen Szewczyk, Jolanthe Kropidlowski, Thais Pereira‐Veiga, Hatice Elmas, Sven Perner, Stefan Steurer, Harriet Wikman, Klaus Pantel, Martin Reck   +16 more
doaj   +1 more source

Enhancing immunotherapy through PD‐L1 upregulation: the promising combination of anti‐PD‐L1 plus mTOR inhibitors

Molecular Oncology
Immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein 1 (PD‐1)/programmed cell death 1 ligand 1 (PD‐L1) pathway have transformed urothelial cancer (UC) therapy.
Anna Hernández‐Prat, Alejo Rodriguez‐Vida, Laura Cardona, Mengjuan Qin, Oriol Arpí‐Llucià, Luis Soria‐Jiménez, Sílvia Menendez, Fabricio Gerel Quimis, Miguel Galindo, Edurne Arriola, Marta Salido, Nuria Juanpere‐Rodero, Federico Rojo, Aura Muntasell, Joan Albanell, Ana Rovira, Joaquim Bellmunt   +16 more
doaj   +1 more source

Clinical Insights Into Hypercalcemia of Malignancy in Childhood

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Hypercalcemia of malignancy (HCM) is a rare but life‐threatening metabolic emergency in children that occurs in less than 1% of pediatric cancer cases, with a reported incidence ranging from 0.4% to 1.0% across different studies. While it is observed in 10%–20% of adult malignancies, pediatric HCM remains relatively uncommon.
Hüseyin Anıl Korkmaz
wiley   +1 more source

Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients

Journal of the Egyptian National Cancer Institute, 2018
Cancer immunotherapy targeting programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) pathway has shown promising results in treatment of non-small cell lung cancer (NSCLC) patients.
Dina M. El-Guindy, Duaa S. Helal, Nesreen M. Sabry, Mohamed Abo El-Nasr   +3 more
doaj   +1 more source